Medivate Partners invests $12 mln in Sillajen
Medivate Partners said Monday it invested $12 million in Sillajen. Busan, South Korea-based Sillajen is an oncolytic immunotherapeutic firm currently in Phase III multi-national clinical development in US, Europe and Asia.
22 March 2016•2 mins read
